Back to News
Market Impact: 0.15
Bronstein, Gewirtz & Grossman LLC Urges Capricor Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
Source: globenewswire.com
Legal & LitigationCompany Fundamentals
A class action lawsuit has been filed against Capricor Therapeutics (NASDAQ: CAPR) and certain officers. The news is a modest negative headline for equity risk, though no financial figures or guidance changes were provided in the article.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly negative
Sentiment Score
-0.20
Ticker Sentiment
CAPR-0.90
More News
- U.S. regulators rush to write crypto rulebook after Clarity Act stalls in Senate
- Meta is breaking out after introducing Muse AI agent. Where the stock is going, according to the charts
- Meta’s Muse AI is exploding in popularity—and already drawing heated backlash from another tech giant
- Lennar shares pop as Berkshire builds almost a 10% stake in beleaguered homebuilder
- Anthropic and OpenAI roll out cheaper models in first release since call for slowdown
- Activist Jana Partners calls for Six Flags sale- WSJ
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- Can Hedge Funds Use ChatGPT? A Control Framework
- Palantir (PLTR) Q4 2025 Earnings: 70% Revenue Growth, Then an 11% Single-Day Crash